Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
45 hedge funds and large institutions have $113M invested in Agile Therapeutics in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 8 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
12% less funds holding
Funds holding: 51 → 45 (-6)
23% less capital invested
Capital invested by funds: $147M → $113M (-$34.3M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.93M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$959K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$728K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$391K |
| 5 |
State Street
Boston,
Massachusetts
|
+$195K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.35M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$428K |
| 3 |
Goldman Sachs
New York
|
-$405K |
| 4 |
Renaissance Technologies
New York
|
-$390K |
| 5 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$254K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Goldman Sachs
New York
| – | -$405K | -24 | Closed |
|
|
52
Renaissance Technologies
New York
| – | -$390K | -23 | Closed |
|
|
RFC
53
Russell Frank Company
Seattle,
Washington
| – | -$254K | -15 | Closed |
|
|
BG
54
BlackRock Group
London,
United Kingdom
| – | -$91K | -5 | Closed |
|
|
CI
55
Cowen Inc
New York
| – | -$86K | -5 | Closed |
|
|
MC
56
Menta Capital
San Francisco,
California
| – | -$87K | -5 | Closed |
|
|
SO
57
STRS Ohio
Columbus,
Ohio
| – | -$35.5K | -2 | Closed |
|
AGRX Hedge Fund Activity: Q3 2015 in Review
45 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q3 2015, worth a combined $113M — down 23% from $147M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of AGRX and 2 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 14 added.
The largest buyer was Opaleye Management, adding an estimated $2.93M. The largest seller was RA Capital Management, cutting an estimated $7.35M.
- 45 institutional investors held Agile Therapeutics (AGRX) as of Q3 2015, down from 51 in Q2 2015.
- Funds reported $113M of Agile Therapeutics stock for Q3 2015, down 23% quarter-over-quarter.
- 2 funds opened new Agile Therapeutics positions in Q3 2015 and 8 closed out, a net change of -6 holders.
- The largest Agile Therapeutics buyer in Q3 2015 was Opaleye Management, an estimated $2.93M added.
- The largest Agile Therapeutics seller in Q3 2015 was RA Capital Management, an estimated $7.35M sold.
Based on aggregated 13F filings for Q3 2015.